Genome-wide study investigating effector genes and polygenic prediction for kidney function in persons with ancestry from Africa and the Americas

By sjmartinez • January 9, 2024

Hughes O, Bentley AR, Breeze CE, Aguet F, Xu X, Nadkarni G, Sun Q, Lin BM, Gilliland T, Meyer MC, Du J, Raffield LM, Kramer H, Morton RW, Gouveia MH, Atkinson EG, Valladares-Salgado A, Wacher-Rodarte N, Dueker ND, Guo X, Hai Y, Adeyemo A, Best LG, Cai J, Chen G, Chong M, Doumatey A, Eales J, Goodarzi MO, Ipp E, Irvin MR, Jiang M, Jones AC, Kooperberg C, Krieger JE, Lange EM, Lanktree MB, Lash JP, Lotufo PA, Loos RJF, Ha My VT, Peralta-Romero J, Qi L, Raffel LJ, Rich SS, Rodriquez EJ, Tarazona-Santos E, Taylor KD, Umans JG, Wen J, Young BA, Yu Z, Zhang Y, Ida Chen YD, Rundek T, Rotter JI, Cruz M, Fornage M, Lima-Costa MF, Pereira AC, Paré G, Natarajan P, Cole SA, Carson AP, Lange LA, Li Y, Perez-Stable EJ, Do R, Charchar FJ, Tomaszewski M, Mychaleckyj JC, Rotimi C, Morris AP, Franceschini N. Genome-wide study investigating effector genes and polygenic prediction for kidney function in persons with ancestry from Africa and the Americas. Cell Genom. 2023 Dec 20:100468. doi: 10.1016/j.xgen.2023.100468. Epub ahead of print. PMID: 38190104.

Tags: admixed populations, Cedars Sinai DoM, Chronic kidney disease, EGFR, Endocrinology, expression quantitative trait locus, fine-mapping, Genome-wide association study, kidney function, multi-ancestry, polygenic scores, Publications

Related Posts

Psychotherapy vs antidepressants in heart failure: Impact of adherence

IsHak WW, Hamilton MA, Diniz MA, Mirocha J, Chernoff R, Hedrick R, Aronow H, Darwish T, Messineo G, Pasini M, Olanisa L, Tetrault E, Arun[...]

Association of Eicosanoids and Eicosanoid-Related Metabolites With Obesity and Cardiometabolic Traits

Chitsazan M, Parekh JK, Grundmann AL, Lau ES, Alotaibi M, Yu B, Rebholz CM, Selvin E, Allen NB, Allison MA, Jain M, Cheng S, Ho[...]

Nirmatrelvir-ritonavir targeting viral persistence in post-COVID-19 condition (long COVID) in the USA (RECOVER-VITAL): a randomised, double-blind, placebo-controlled, phase 2 trial

Baden LR, Shah NS, Liu STH, Cohen J, Moy J, Kumar A, McComsey GA, Chen P, Floris-Moore M, Singer NG, Fernandez I, Slandzicki AJ, Wiley[...]